NOXXON Pharma Announces Name Change to “TME Pharma” and New Trade Symbol

BERLIN–(BUSINESS WIRE)–Regulatory news:

TME Pharma S.A., a biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announced today it officially changed its corporate name from “NOXXON Pharma NV” to “TME Pharma SA.” and the ticker symbol for the Company’s ordinary shares on Euronext Growth Paris will change from “ALNOX” to “ALTME”. Trading under the new name and ticker symbol will begin at the market open on Tuesday July 19, 2022. July. 2022.

TME Pharma also announced the launch of its new corporate website which can be viewed at www.tmepharma.com.

Aram Mangasarian, CEO of TME Pharmacommented : “Over the past few years, our company has evolved into an oncology biotech with a clear focus on advancing tumor microenvironment-modifying approaches – TME – where our technology has shown strong signs of efficacy. The name changes to TME Pharma marks this successful transformation for our team and our stakeholders. Our strategy will prioritize and continue to support opportunities with the fastest path to approval. Following the exceptional results recently announced in our glioblastoma program, we will focus our capabilities to successfully develop our lead asset NOX-A12 and achieve this milestone in this indication first.

All shares of NOXXON Pharma NV will become shares of TME Pharma SA at parity without intervention of the current shareholders of the company.

About TME Pharma

TME Pharma is a clinical-stage company focused on the development of new therapies for the treatment of the most aggressive cancers. The Company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and cancer immunity cycle by breaking down tumor protective barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharmacy This approach works in combination with other forms of treatment to weaken tumor defenses and allow for greater therapeutic impact. In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in patients with newly diagnosed brain cancer who will not clinically benefit from standard chemotherapy. TME Pharma provided front-line data from the three NOX-A12 dose escalation cohorts combined with radiation therapy from the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA’s expansion arms are evaluating the safety and efficacy of NOX-A12 in other combinations where interim results from the triple combination of NOX-A12, radiation therapy, and bevacizumab suggest even greater responses. deeper and longer lasting. NOX-A12 in combination with radiation therapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma provided the first final data with an encouraging overall survival and safety profile from its combined NOX-A12 trial with Keytruda® in patients with metastatic colorectal and pancreatic cancer, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered into its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to evaluate further on the safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The trial design is under discussion with regulatory authorities in the United States and Europe. The company’s second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharmacy is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit TME Pharmacy on LinkedIn and Twitter.

About the GLORIA study

GLORIA (NCT04121455) is TME Pharmacy dose-escalating, phase 1/2 study of NOX-A12 in combination with radiation therapy in patients with partially resected or unresected glioblastoma (brain cancer) with an unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA is further evaluating the safety and efficacy of NOX-A12 in three additional arms combining NOX-A12 with: A. radiation therapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiation therapy and pembrolizumab.

About the OPTIMUS study

OPTIMUS (NCT04901741) is TME Pharmacy Planned, Open-Label, Two-Arm Phase 2 Study of NOX-A12 in Combination with Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-Paclitaxel in Patients With Stable Microsatellite Metastatic Pancreatic Cancer .

Disclaimer

Translations of any press release into languages ​​other than English are for the convenience of non-English speaking audiences only. The company has attempted to provide an accurate translation of the original English text, but due to nuances of translating into another language, slight differences may exist. This press release includes certain information that contains “forward-looking statements”. Forward-looking statements are based on TME Pharma current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks inherent in oncology drug development, including clinical trials and timing and TME Pharmacy ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. The forward-looking statements contained in this announcement are made as of this date, and TME Pharma assumes no obligation to update this information, except as required by applicable law.

Garland K. Long